Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors

doi:10.1186/1471-2407-8-346

BMC Cancer
Volume 8

Viewing options:

Abstract
Full text
PDF (1.6MB)

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Ouellet V
Ling TH
Normandin K
Madore J
Lussier C
Barrès V
Bachvarov D
Rancourt C
Tonin PN
Provencher DM
Mes-Masson AM

on PubMed

Ouellet V
Ling TH
Normandin K
Madore J
Lussier C
Barrès V
Bachvarov D
Rancourt C
Tonin PN
Provencher DM
Mes-Masson AM
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Research article

Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors

Véronique Ouellet¹ , Tak Hay Ling¹^,2 , Karine Normandin¹ , Jason Madore¹ , Christian Lussier³ , Véronique Barrès¹ , Dimcho Bachvarov⁴^,5 , Claudine Rancourt⁶ , Patricia N Tonin⁷^,8^,9 , Diane M Provencher¹^,10^,11 and Anne-Marie Mes-Masson¹^,11

¹Centre de recherche du centre hospitalier de l'Université de Montréal (CHUM)/Institut du cancer de Montréal, Montreal, Canada

²Department of Obstetric/Gynecology, Taipei Medical University-Wan Fang Hospital, Taipei, Taiwan

³Department of Pathology, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Canada

⁴Department of Medicine, Université Laval, Quebec, Canada

⁵Centre de recherche de l'Hôtel-Dieu de Québec, Quebec, Canada

⁶Department of Microbiology-Infectiology, Université de Sherbrooke, Sherbrooke, Quebec, Canada

⁷Department of Human Genetics, McGill University, Montreal, Canada

⁸Research Institute of the McGill University Health Centre, Montreal, Canada

⁹Department of Medicine, McGill University, Montreal, Canada

¹⁰Division of Gynecologic Oncology/Université de Montréal, Montreal, Canada

¹¹Department of Medicine, Université de Montréal, Montreal, Canada

author email corresponding author email

BMC Cancer 2008, 8:346doi:10.1186/1471-2407-8-346


Published:	26 November 2008

Abstract

Background

Serous epithelial ovarian tumors can be subdivided into benign (BOV), low malignant potential (LMP) or borderline and invasive (TOV) tumors. Although the molecular characteristics of serous BOV, LMP and low grade (LG) TOV tumors has been initiated, definitive immunohistochemical markers to distinguish between these tumor types have not been defined.

Methods

In the present study, we used a tissue array composed of 27 BOVs, 78 LMPs and 23 LG TOVs to evaluate the protein expression of a subset of selected candidates identified in our previous studies (Ape1, Set, Ran, Ccne1 and Trail) or known to be implicated in epithelial ovarian cancer disease (p21, Ccnb1, Ckd1).

Results

Statistically significant difference in protein expression was observed for Ccnb1 when BOV tumors were compared to LMP tumors (p = 0.003). When BOV were compared to LG TOV tumors, Trail was significantly expressed at a higher level in malignant tumors (p = 0.01). Expression of p21 was significantly lower in LG tumors when compared with either BOVs (p = 0.03) or LMPs (p = 0.001). We also observed that expression of p21 was higher in LMP tumors with no (p = 0.02) or non-invasive (p = 0.01) implants compared to the LMP associated with invasive implants.

Conclusion

This study represents an extensive analyse of the benign and highly differentiated ovarian disease from an immunohistochemical perspective.